Company Number: 14265949

Analysis Date: 2025-07-20 18:45 UTC

1. Credit Opinion: DECLINE
   AA PHARMPLUS LTD shows a concerning deterioration in its financial position over the latest reported year. Net current assets plummeted from £13,473 in 2023 to only £259 in 2024, indicating a near break-even working capital position. More critically, current liabilities have surged almost ninefold from £3,607 to £32,387, suggesting possible liquidity stress and a higher risk of payment difficulties. The very low net asset base (£259) undermines the company's financial resilience and ability to absorb shocks or fund growth. Given this sharp decline and micro-entity scale, approval for new credit facilities is not advisable without substantive improvement or additional security.

2. Financial Strength:
   The balance sheet reflects a fragile financial structure. Fixed assets are not disclosed, implying limited tangible asset backing. Current assets increased modestly (£17k to £33k), but current liabilities ballooned disproportionately, eroding net working capital to a marginal £259. The negligible shareholders' funds highlight minimal equity cushion. This thin capital base and escalating liabilities expose the company to elevated solvency risk, limiting its ability to withstand operational setbacks or economic downturns.

3. Cash Flow Assessment:
   While cash flow details are not explicitly provided, the large jump in current liabilities relative to current assets suggests tightening liquidity. The company holds just enough current assets to cover short-term obligations, leaving almost no buffer for unforeseen expenses or delayed receivables. With only two employees and a micro account category, operational cash generation is likely limited. Without visible retained earnings or accumulated reserves, the ability to generate positive cash flow internally appears weak.

4. Monitoring Points:

• Track the trend in current liabilities closely to detect further increases or overdue payables.
• Monitor cash balances and liquidity ratios quarterly to ensure short-term obligations can be met.
• Review any changes in shareholder equity or capital injections that would strengthen the balance sheet.
• Watch for timely filing of accounts and returns to assess ongoing compliance and financial transparency.
• Evaluate operational performance indicators (if available) for signs of revenue growth or margin improvement.